&lt;p&gt;Medication-Induced Oral Hyperpigmentation: A Systematic Review&lt;/p&gt;

Binmadi, Nada O.; Bawazir, Maram; Alhindi, Nada A.; Mawardi, Hani; Mansour, Ghada; Alhamed, Sana; Alfarabi, Sarah; Akeel, Sara; Almazrooa, Soulafa

doi:10.2147/ppa.s275783

Cited by 17 publications

(15 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the systematic review based on case reports and series thereof published in 2020 by Binmadi et al . ( 10 ) they reported that the medication that was more frequently associated with these pigmentations is imatinib. The hyperpigmentation caused by this prescription has been described in several studies, such as the ones published by Mcpherson et al .…”

Section: Discussionmentioning

confidence: 99%

“…There are drugs identified in systematic reviews as inductors of oral pigmentation, but they do not have this ADR registered in their SCP and that is the reason why we could not find them in our search. Among them we can highlight: golimumab, whose SCP does not mention hyperpigmentation neither in the oral cavity nor in the skin ( 15 ); ketoconazole, not described in any SPC ( 10 ); amlodipine, whose SPC only describes change of pigmentation on the skin ( 34 ); retigabine, an antiepileptic drug which has not been commercialised in Europe since 2018; clofazimine, an antileprotic whose SPC is only associated with skin lesions.…”

Section: Discussionmentioning

confidence: 99%

“…Patients presenting these lesions must be monitored and a proper follow-up of the lesions needs to be done in order to avoid misdiagnosis. In addition, a correct record of the ADR in the oral cavity in response to the prescription needs to be made ( 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

“…This has been widely documented in publications that highlight the cause-and-effect relationship between the administration of a specific drug and the appearance of pigmented lesions in the oral cavity ( 9 ). These lesions may appear immediately after the administration of a medicine or after a longer period such as days or even years ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Medication related to pigmentation of oral mucosa

Mallagray-Montero¹,

Moreno-López²,

Cerero-Lapiedra³

et al. 2022

Med Oral

View full text Add to dashboard Cite

Background The diagnosis of oral melanotic lesions is, more often than not, challenging in the clinical practice due to the fact that there are several reasons which may cause an increase in pigmentation on localized or generalized areas. Among these, medication stands out. Material and Methods In this work, we have carried out a review in the reference pharma database: Micromedex® followed by a review of the scientific published literature to analyse coincidences and possible discrepancies. Results Our findings show that there are several prescription drugs that can cause pigmented lesions in the oral mucosa. This must be known by clinicians in order to properly diagnose pigmented lesions. We have identified a set of 21 medicaments which cause these lesions, some of which are used frequently in the clinic, such as Metronidazole, Amitriptyline, conjugated oestrogens and Chlorhexidine gluconate. We also found discrepancies with the data published in specialized literature, some of which wasn’t reflected in the Summary of Product Characteristics. Conclusions Our work highlights the importance of the proper communication of adverse drug reactions (ADR) by health professionals in order to provide thorough and accurate information and diagnosis. Key words: Adverse drug reactions, oral pigmentation, micromedex.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Medication related to pigmentation of oral mucosa

Mallagray-Montero¹,

Moreno-López²,

Cerero-Lapiedra³

et al. 2022

Med Oral

View full text Add to dashboard Cite

show abstract

“…Hyperpigmentation is a common condition characterized by skin darkening due to the overproduction of the pigment melanin. It has many causes including excessive sun exposure (solar lentigo), 1 changes in female hormones (melasma), 2 acne (post‐inflammatory hyperpigmentation), 3 and certain medications (minocycline) 4,5 . Hyperpigmentation is a cosmetic concern that can have a significant impact on self‐esteem and quality of life 6‐8 and is more prevalent among dark‐skinned individuals although most skin types can be affected 9‐11 .…”

Section: Introductionmentioning

confidence: 99%

An Open‐Label Study Assessing the Efficacy and Tolerability of a Skincare Regimen in Subjects of Different Ethnicities with Moderate‐to‐Severe Hyperpigmentation

Wenner¹,

Ramberg²

2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Hyperpigmentation is a common cosmetic concern that significantly impacts self‐esteem. A skincare regimen has been developed to improve the appearance, tone, texture, and luminosity of subjects with facial hyperpigmentation (Even Up® Hyperpigmentation Regimen; Colorescience, Inc., Carlsbad, CA). Aims The objective of this open‐label trial was to assess the efficacy and tolerability of this regimen for treating facial hyperpigmentation. Patients/Methods Subjects with moderate‐to‐severe facial hyperpigmentation (N = 33) were randomized to those not using prescription, advanced or physician‐dispensed skin care products (Group A, n = 23) and those currently using prescription, advanced or physician‐dispensed skincare products for facial hyperpigmentation (Group B, n = 10). Both groups were provided three skincare products comprising the hyperpigmentation regimen and instructions for use. Subjects were evaluated at baseline and Weeks 2, 4, 8 and 12. Results The overall median (range) baseline MASI score at baseline was 9.0 (2, 31), decreasing by 0.0 (−7, 0) points at Week 2 (p = 0.002), 0.6 (−8, 0) points at Week 4 (p < 0.0001), 1.5 (−16, 0) points by Week 8 (p < 0.0001) and 2.4 (−20, 0) points at Week 12 (p < 0.0001). At Week 12, the overall median improvement in MASI score was 26% and higher for Group B (32% vs. 22%). By Week 2, subjects reported lighter, less noticeable brown spots (76%), brighter, more luminous skin (88%), more even skin tone (67%), and healthier look and feel (85%). Improvements continued throughout the study. No adverse events were observed or reported. Conclusions This regimen addresses facial hyperpigmentation and protects skin against the damaging effects of ultraviolet and high energy visible light (HEV). It is safe to use on all skin types and tones.

show abstract